Previous Page  108 / 161 Next Page
Information
Show Menu
Previous Page 108 / 161 Next Page
Page Background

Conformational Ensembles from Experimental Data

and Computer Simulations

Poster Abstracts

104 

69-POS

Board 29

Coregulators Select Conformational States from Drug Specific Peroxisome Proliferator-

activated Receptor Gamma (PPARγ) Conformational Ensembles

Michelle Nemetchek

1,2,3

, Ian M. Chrisman

1,2

, Travis S. Hughes

1,2,3

.

2

The University of Montana, Missoula, MT, USA,

1

The University of Montana, Missoula, MT,

USA,

3

The University of Montana, Missoula, MT, USA.

Nuclear receptors are transcription factors that, when bound to agonists, cause transcription of

regulatory genes. Peroxisome Proliferator-activated receptor gamma (PPARγ) is a nuclear

receptor that is an important target of many FDA-approved type II diabetes drugs. When agonist

bound, PPARγ recruits the coactivator Mediator complex subunit 1 (MED1), which is part of the

mediator complex and triggers transcription of PPARγ-regulated genes. These genes control

adipogenesis and lipid storage, and may enhance insulin sensitivity. When bound to inverse

agonists, PPARγ complexes with Nuclear Receptor Corepressor I (NCoR1) and is blocked from

transcriptional activation. By using Time-Resolved Förster Resonance Energy Transfer (TR-

FRET), PPARγ binding drugs are shown to produce differing affinities for MED1 and NCoR1

peptides which contain the essential nuclear receptor binding motif. We covalently label PPARγ

with a fluorine containing probe on the AF2 surface (the surface where coregulators have been

demonstrated to interact) and use Fluorine-19 (19F) Nuclear Magnetic Resonance to determine

how coregulator binding affects this surface. The AF2 surface conformations are highly similar

for both full agonist bound and full agonist and MED1 co-bound states, similarly inverse

agonists induce conformations that are relatively unchanged by NCoR1 binding. Our data also

suggest that coregulators select conformations from a preexisting ensemble which is highly drug

specific. This work links structure of the LBD to the functional outcome of transcription.